Incretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.